Tsuruoka A, Matsuba I, Toyota T, Isshiki G, Nagataki S, Ikeda Y
Department of General Internal Medicine, Jikei University Kashiwa Hospital, Japan.
Diabetes Res Clin Pract. 1995 Jun;28(3):191-9. doi: 10.1016/0168-8227(95)01101-i.
We determined the prevalence of antibodies to glutamic acid decarboxylase (anti-GAD) in Japanese diabetic patients. Anti-GAD were detected by RIP Anti-GAD Hoechst, which is a new sensitive radioimmunoassay (RIA) kit using purified pig brain GAD as the antigen. One thousand nine hundred Japanese patients were collected by the Study Group for Antibodies to GAD. The prevalence of anti-GAD in the subjects of this study was: 35.4% (326/921) in all patients with IDDM, 50.3% (96/191) in patients with IDDM less than 1-year duration, 4.3% (29/680) in NIDDM, 37.9% (39/103) in slowly progressive IDDM, 10.5% (4/38) in gestational diabetes mellitus, 0% (0/27) in impaired glucose tolerance, 4.8% (6/124) in the school children with glycosuria, 2.1% (1/47) in the relatives of IDDM and 5.0% (1/20) in neurological diseases without diabetes. The prevalence in normal subjects was 2.2% (7/323). Anti-GAD are frequently detected by the RIA kit in patients with IDDM of short duration and this assay may be useful for population screening for IDDM and for better understanding of its pathogenesis.
我们测定了日本糖尿病患者中谷氨酸脱羧酶抗体（抗GAD）的流行情况。抗GAD通过RIP抗GAD Hoechst检测，这是一种新型灵敏放射免疫分析（RIA）试剂盒，以纯化的猪脑GAD作为抗原。GAD抗体研究组收集了1900名日本患者。本研究对象中抗GAD的流行情况如下：所有胰岛素依赖型糖尿病（IDDM）患者中为35.4%（326/921），病程小于1年的IDDM患者中为50.3%（96/191），非胰岛素依赖型糖尿病（NIDDM）患者中为4.3%（29/680），缓慢进展型IDDM患者中为37.9%（~39/103），妊娠糖尿病患者中为10.5%（4/38），糖耐量受损患者中为0%（0/27），糖尿症学童中为4.8%（6/124），IDDM患者亲属中为2.1%（1/47），无糖尿病的神经疾病患者中为5.0%（1/20）。正常受试者中的流行率为2.2%（7/323）。通过该RIA试剂盒在病程短的IDDM患者中经常检测到抗GAD，该检测方法可能有助于IDDM的人群筛查及其发病机制的深入了解。
